Acute Lymphoblastic Leukemia Therapeutics Market : Release Latest Trends & Industry Vision 2026
Acute
lymphoblastic leukemia (ALL) is a type of cancer affecting
the bone marrow and blood. The condition is characterized by
overproduction of immature white blood cells, also known as
lymphoblast. The immature or abnormal cells are unable to function
properly and build up around the healthy cells. Patients diagnosed
with ALL are highly susceptible to recurrent infections, anemia,
bleeding and bruising easily as the bone marrow is unable to form
adequate numbers of red blood cells, white blood cells, and
platelets. The cancer is characterized with high progression rate,
and can be fatal if not treated within few months. The cancerous
cells have the potential to spread to other organs of the body
including lymph nodes, liver, spleen, and the central nervous system.
The common symptoms of the condition include renal failure,
pneumonia, respiratory distress, and bone pain. Acute lymphocytic
leukemia is the most common type of cancer in children, where timely
treatment and diagnosis results in efficient cure of the condition.
Regional Dynamics
Regional segmentation of the global acute
lymphoblastic leukemia therapeutics market by Coherent Market
Insights comprises North America, Latin America, Europe, Asia
Pacific, Middle East, and Africa. North America is expected to hold a
dominant position in the global acute lymphoblastic leukemia
therapeutics market over the forecast period, owing to rising
prevalence of the disease and rising number of clinical trials
undertaken by organizations in the region to address the unmet
medical needs of patients. According to the American Cancer Society,
2016, an estimated 5,970 new ALL diagnoses and 1,440 deaths from ALL
were registered in 2017. Also, according to the St. Jude Children’s
Research Hospital, about 3,000 people aged below 20 years are found
to have acute lymphoblastic leukemia each year in the U.S.
Moreover, the St. Jude Children’s Research
Hospital, U.S. is focusing on improving outcomes for children with
leukemia by undertaking clinical trials to develop novel therapeutics
for the condition. For instance, in 2012, the St. Jude Children’s
Research Hospital initiated trials for ALLR18 for pediatric relapsed
or refractory precursor B-cell acute lymphoblastic leukemia.
Moreover, in 2015, Juno Therapeutics, Inc. developed JCAR015
(CD19-targeted CAR T cells), which is currently in the Phase 2
clinical trial, indicated for treating adults with relapsed or
refractory B-cell acute lymphoblastic leukemia (B-ALL).
Competitive Analysis
Manufacturers in the market are focusing on
introducing CAR-T cell therapies through strategic collaborations,
which is expected to increase the clinical outcomes for ALL. For
instance, in 2014, Pfizer, Inc. and Collectis collaborated to develop
novel CAR-T immunotherapies. The companies initiated Phase 1 clinical
trial for UCART19 in 2016, indicated for pediatric patients with
relapsed or refractory B-ALL.
Key players operating in the global acute
lymphoblastic leukemia therapeutics market include Novartis
Pharmaceuticals, Pfizer Inc., Genzyme Corporation, GlaxoSmithKline
Plc., ERYTECH Pharma, Talon Therapeutic, Inc., Sigma-Tau
Pharmaceuticals, Inc., Spectrum Pharmaceuticals, Inc. F. Hoffmann-La
Roche Ltd., Biogen Idec, Inc., Bristol-Myers Squibb, and Celgene
Corporation.
Inquire Here Before Purchase of Research Report @
https://www.coherentmarketinsights.com/insight/talk-to-analyst/1606
Market Taxonomy
On the basis of drug type, global acute
lymphoblastic leukemia therapeutics market is segmented into:
-
Chemotherapy Drugs
-
Nelarabine (Arranon)
-
Blinatumomab (Blincyto)
-
Clofarabine (Clolar)
-
Erwinia (Erwinase)
-
Pegaspargase (Oncaspar)
-
Vincristine (Marqibo)
-
Others
-
-
Immunotherapy Drugs
-
Tisagenlecleucel (Kymriah)
-
-
Targeted Therapy Drugs
-
Imatinib (Gleevec)
-
Dasatinib (Sprycel)
-
Nilotinib (Tasigna)
-
Others
-
-
Others
On the basis of indication, global acute
lymphoblastic leukemia therapeutics market is segmented into:
-
Precursor B Cell ALL
-
Mature B Cell ALL
-
Precursor T Cell ALL
On the basis of distribution channel, the
global acute lymphoblastic leukemia therapeutics market is segmented
into:
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
On the basis of region, the global acute
lymphoblastic leukemia therapeutics market is segmented into:
-
North America
-
Latin America
-
Europe
-
Asia Pacific
-
Middle East
-
Africa
About Coherent
Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702

Comments
Post a Comment